Loading…
Synthesis and pharmacological evaluation of new 5-(cyclo)alkyl-5-phenyl- and 5-spiroimidazolidine-2,4-dione derivatives. Novel 5-HT1A receptor agonist with potential antidepressant and anxiolytic activity
The synthesis of 5-(cyclo)alkyl-5-phenyl- and 5-spiroimidazolidine-2,4-dione derivatives with an arylpiperazinylpropyl moiety (12-23) and their in vitro and in vivo pharmacological properties and molecular characteristics were described. The investigated compounds exhibited high affinity for 5-HT(1A...
Saved in:
Published in: | European journal of medicinal chemistry 2010-04, Vol.45 (4), p.1295-1303 |
---|---|
Main Authors: | , , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c336t-b152ef9e7f871bef7b9164ba45d2d841b3a08e01f845e60d723fec023eb4c9663 |
---|---|
cites | |
container_end_page | 1303 |
container_issue | 4 |
container_start_page | 1295 |
container_title | European journal of medicinal chemistry |
container_volume | 45 |
creator | CZOPEK, Anna BYRTUS, Hanna KOLACZKOWSKI, Marcin PAWLOWSKI, Maciej DYBALA, Małgorzata NOWAK, Gabriel TATARCZYNSKA, Ewa WESOLOWSKA, Anna CHOJNACKA-WOJCIK, Ewa |
description | The synthesis of 5-(cyclo)alkyl-5-phenyl- and 5-spiroimidazolidine-2,4-dione derivatives with an arylpiperazinylpropyl moiety (12-23) and their in vitro and in vivo pharmacological properties and molecular characteristics were described. The investigated compounds exhibited high affinity for 5-HT(1A) (13-22) and 5-HT(2A) (18, 20, 21, 23) receptors and diversified pharmacological profile. Compounds 17, 20 and 22 showed antagonistic, partial agonistic and agonistic activity, respectively, toward 5-HT(1A) receptor and they were investigated as potential antidepressants and/or anxiolytics. The most interesting compound 22 (1-[3-(4-(2-methoxyphenyl)piperazin-1-yl)propyl]-3',4'-dihydro-2'H-spiro[imidazolidine-4,1'-naphthalene]-2,5-dione), a pre- and postsynaptic 5-HT(1A) receptor agonist produced an antidepressant-like effect, which was more pronounced than that of imipramine in the forced swim test in mice, without affecting locomotor activity. Moreover, compound 22 produced a weak anxiolytic-like effect in the four-plate test in mice. Molecular docking studies of compound 22 to the homology model of the 5-HT(1A) receptor showed that a 3',4'-dihydro-2'H-spiro[imidazolidine-4,1'-naphthalene]-2,5-dione moiety played an important role in stabilizing the ligand-receptor complex. |
doi_str_mv | 10.1016/j.ejmech.2009.11.053 |
format | article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_733707447</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>733707447</sourcerecordid><originalsourceid>FETCH-LOGICAL-c336t-b152ef9e7f871bef7b9164ba45d2d841b3a08e01f845e60d723fec023eb4c9663</originalsourceid><addsrcrecordid>eNpFkc1u1DAURi0EokPhDRDyBgESDv6LM7OsKtoiVbCgrCPHuWk8OHawPVPCM_JQuJ0BVvcuvvPdKx2EXjJaMcrUh20F2wnMWHFKNxVjFa3FI7RijVoTwWv5GK0o54LUXMgT9CylLaW0VpQ-RScFUVRxsUK_vy4-j5Bswtr3eB51nLQJLtxaox2GvXY7nW3wOAzYwx2uyVuzGBfeafd9caQm8wi-LA94TdJsY7CT7fWv4GxvPRD-XpK-NADuIdp9adtDqvDnsAdXiKsbdoYjGJhziFjfBm9Txnc2j3gOGXy25Q9dRg9zhJTK-nBL-582uCVbg7UpnTYvz9GTQbsEL47zFH27-HhzfkWuv1x-Oj-7JkYIlUnHag7DBpph3bAOhqbbMCU7Leue92vJOqHpGigb1rIGRfuGiwEM5QI6aTZKiVP05tA7x_BjBym3k00GnNMewi61jRANbaRsSlIekiaGlCIM7RztpOPSMtrea2y37UFje6-xZawtGgv26nhg103Q_4P-eiuB18eATsXTELU3Nv3PccV4eUH8AYBDrA8</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>733707447</pqid></control><display><type>article</type><title>Synthesis and pharmacological evaluation of new 5-(cyclo)alkyl-5-phenyl- and 5-spiroimidazolidine-2,4-dione derivatives. Novel 5-HT1A receptor agonist with potential antidepressant and anxiolytic activity</title><source>ScienceDirect Journals</source><creator>CZOPEK, Anna ; BYRTUS, Hanna ; KOLACZKOWSKI, Marcin ; PAWLOWSKI, Maciej ; DYBALA, Małgorzata ; NOWAK, Gabriel ; TATARCZYNSKA, Ewa ; WESOLOWSKA, Anna ; CHOJNACKA-WOJCIK, Ewa</creator><creatorcontrib>CZOPEK, Anna ; BYRTUS, Hanna ; KOLACZKOWSKI, Marcin ; PAWLOWSKI, Maciej ; DYBALA, Małgorzata ; NOWAK, Gabriel ; TATARCZYNSKA, Ewa ; WESOLOWSKA, Anna ; CHOJNACKA-WOJCIK, Ewa</creatorcontrib><description>The synthesis of 5-(cyclo)alkyl-5-phenyl- and 5-spiroimidazolidine-2,4-dione derivatives with an arylpiperazinylpropyl moiety (12-23) and their in vitro and in vivo pharmacological properties and molecular characteristics were described. The investigated compounds exhibited high affinity for 5-HT(1A) (13-22) and 5-HT(2A) (18, 20, 21, 23) receptors and diversified pharmacological profile. Compounds 17, 20 and 22 showed antagonistic, partial agonistic and agonistic activity, respectively, toward 5-HT(1A) receptor and they were investigated as potential antidepressants and/or anxiolytics. The most interesting compound 22 (1-[3-(4-(2-methoxyphenyl)piperazin-1-yl)propyl]-3',4'-dihydro-2'H-spiro[imidazolidine-4,1'-naphthalene]-2,5-dione), a pre- and postsynaptic 5-HT(1A) receptor agonist produced an antidepressant-like effect, which was more pronounced than that of imipramine in the forced swim test in mice, without affecting locomotor activity. Moreover, compound 22 produced a weak anxiolytic-like effect in the four-plate test in mice. Molecular docking studies of compound 22 to the homology model of the 5-HT(1A) receptor showed that a 3',4'-dihydro-2'H-spiro[imidazolidine-4,1'-naphthalene]-2,5-dione moiety played an important role in stabilizing the ligand-receptor complex.</description><identifier>ISSN: 0223-5234</identifier><identifier>EISSN: 1768-3254</identifier><identifier>DOI: 10.1016/j.ejmech.2009.11.053</identifier><identifier>PMID: 20060623</identifier><identifier>CODEN: EJMCA5</identifier><language>eng</language><publisher>Kidlington: Elsevier</publisher><subject>Animals ; Anti-Anxiety Agents - chemical synthesis ; Anti-Anxiety Agents - chemistry ; Anti-Anxiety Agents - pharmacology ; Antidepressive Agents - chemical synthesis ; Antidepressive Agents - chemistry ; Antidepressive Agents - pharmacology ; Biological and medical sciences ; Imidazolidines - chemical synthesis ; Imidazolidines - chemistry ; Imidazolidines - pharmacology ; Magnetic Resonance Spectroscopy ; Medical sciences ; Mice ; Models, Molecular ; Motor Activity - drug effects ; Neuropharmacology ; Neurotransmitters. Neurotransmission. Receptors ; Pharmacology. Drug treatments ; Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer ; Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer..., (alzheimer disease) ; Psycholeptics: tranquillizer, neuroleptic ; Psychology. Psychoanalysis. Psychiatry ; Psychopharmacology ; Rats ; Serotonin 5-HT1 Receptor Agonists ; Serotonin Receptor Agonists - chemical synthesis ; Serotonin Receptor Agonists - chemistry ; Serotonin Receptor Agonists - pharmacology ; Serotoninergic system</subject><ispartof>European journal of medicinal chemistry, 2010-04, Vol.45 (4), p.1295-1303</ispartof><rights>2015 INIST-CNRS</rights><rights>Copyright (c) 2009 Elsevier Masson SAS. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c336t-b152ef9e7f871bef7b9164ba45d2d841b3a08e01f845e60d723fec023eb4c9663</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=22612707$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/20060623$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>CZOPEK, Anna</creatorcontrib><creatorcontrib>BYRTUS, Hanna</creatorcontrib><creatorcontrib>KOLACZKOWSKI, Marcin</creatorcontrib><creatorcontrib>PAWLOWSKI, Maciej</creatorcontrib><creatorcontrib>DYBALA, Małgorzata</creatorcontrib><creatorcontrib>NOWAK, Gabriel</creatorcontrib><creatorcontrib>TATARCZYNSKA, Ewa</creatorcontrib><creatorcontrib>WESOLOWSKA, Anna</creatorcontrib><creatorcontrib>CHOJNACKA-WOJCIK, Ewa</creatorcontrib><title>Synthesis and pharmacological evaluation of new 5-(cyclo)alkyl-5-phenyl- and 5-spiroimidazolidine-2,4-dione derivatives. Novel 5-HT1A receptor agonist with potential antidepressant and anxiolytic activity</title><title>European journal of medicinal chemistry</title><addtitle>Eur J Med Chem</addtitle><description>The synthesis of 5-(cyclo)alkyl-5-phenyl- and 5-spiroimidazolidine-2,4-dione derivatives with an arylpiperazinylpropyl moiety (12-23) and their in vitro and in vivo pharmacological properties and molecular characteristics were described. The investigated compounds exhibited high affinity for 5-HT(1A) (13-22) and 5-HT(2A) (18, 20, 21, 23) receptors and diversified pharmacological profile. Compounds 17, 20 and 22 showed antagonistic, partial agonistic and agonistic activity, respectively, toward 5-HT(1A) receptor and they were investigated as potential antidepressants and/or anxiolytics. The most interesting compound 22 (1-[3-(4-(2-methoxyphenyl)piperazin-1-yl)propyl]-3',4'-dihydro-2'H-spiro[imidazolidine-4,1'-naphthalene]-2,5-dione), a pre- and postsynaptic 5-HT(1A) receptor agonist produced an antidepressant-like effect, which was more pronounced than that of imipramine in the forced swim test in mice, without affecting locomotor activity. Moreover, compound 22 produced a weak anxiolytic-like effect in the four-plate test in mice. Molecular docking studies of compound 22 to the homology model of the 5-HT(1A) receptor showed that a 3',4'-dihydro-2'H-spiro[imidazolidine-4,1'-naphthalene]-2,5-dione moiety played an important role in stabilizing the ligand-receptor complex.</description><subject>Animals</subject><subject>Anti-Anxiety Agents - chemical synthesis</subject><subject>Anti-Anxiety Agents - chemistry</subject><subject>Anti-Anxiety Agents - pharmacology</subject><subject>Antidepressive Agents - chemical synthesis</subject><subject>Antidepressive Agents - chemistry</subject><subject>Antidepressive Agents - pharmacology</subject><subject>Biological and medical sciences</subject><subject>Imidazolidines - chemical synthesis</subject><subject>Imidazolidines - chemistry</subject><subject>Imidazolidines - pharmacology</subject><subject>Magnetic Resonance Spectroscopy</subject><subject>Medical sciences</subject><subject>Mice</subject><subject>Models, Molecular</subject><subject>Motor Activity - drug effects</subject><subject>Neuropharmacology</subject><subject>Neurotransmitters. Neurotransmission. Receptors</subject><subject>Pharmacology. Drug treatments</subject><subject>Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer</subject><subject>Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer..., (alzheimer disease)</subject><subject>Psycholeptics: tranquillizer, neuroleptic</subject><subject>Psychology. Psychoanalysis. Psychiatry</subject><subject>Psychopharmacology</subject><subject>Rats</subject><subject>Serotonin 5-HT1 Receptor Agonists</subject><subject>Serotonin Receptor Agonists - chemical synthesis</subject><subject>Serotonin Receptor Agonists - chemistry</subject><subject>Serotonin Receptor Agonists - pharmacology</subject><subject>Serotoninergic system</subject><issn>0223-5234</issn><issn>1768-3254</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2010</creationdate><recordtype>article</recordtype><recordid>eNpFkc1u1DAURi0EokPhDRDyBgESDv6LM7OsKtoiVbCgrCPHuWk8OHawPVPCM_JQuJ0BVvcuvvPdKx2EXjJaMcrUh20F2wnMWHFKNxVjFa3FI7RijVoTwWv5GK0o54LUXMgT9CylLaW0VpQ-RScFUVRxsUK_vy4-j5Bswtr3eB51nLQJLtxaox2GvXY7nW3wOAzYwx2uyVuzGBfeafd9caQm8wi-LA94TdJsY7CT7fWv4GxvPRD-XpK-NADuIdp9adtDqvDnsAdXiKsbdoYjGJhziFjfBm9Txnc2j3gOGXy25Q9dRg9zhJTK-nBL-582uCVbg7UpnTYvz9GTQbsEL47zFH27-HhzfkWuv1x-Oj-7JkYIlUnHag7DBpph3bAOhqbbMCU7Leue92vJOqHpGigb1rIGRfuGiwEM5QI6aTZKiVP05tA7x_BjBym3k00GnNMewi61jRANbaRsSlIekiaGlCIM7RztpOPSMtrea2y37UFje6-xZawtGgv26nhg103Q_4P-eiuB18eATsXTELU3Nv3PccV4eUH8AYBDrA8</recordid><startdate>20100401</startdate><enddate>20100401</enddate><creator>CZOPEK, Anna</creator><creator>BYRTUS, Hanna</creator><creator>KOLACZKOWSKI, Marcin</creator><creator>PAWLOWSKI, Maciej</creator><creator>DYBALA, Małgorzata</creator><creator>NOWAK, Gabriel</creator><creator>TATARCZYNSKA, Ewa</creator><creator>WESOLOWSKA, Anna</creator><creator>CHOJNACKA-WOJCIK, Ewa</creator><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20100401</creationdate><title>Synthesis and pharmacological evaluation of new 5-(cyclo)alkyl-5-phenyl- and 5-spiroimidazolidine-2,4-dione derivatives. Novel 5-HT1A receptor agonist with potential antidepressant and anxiolytic activity</title><author>CZOPEK, Anna ; BYRTUS, Hanna ; KOLACZKOWSKI, Marcin ; PAWLOWSKI, Maciej ; DYBALA, Małgorzata ; NOWAK, Gabriel ; TATARCZYNSKA, Ewa ; WESOLOWSKA, Anna ; CHOJNACKA-WOJCIK, Ewa</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c336t-b152ef9e7f871bef7b9164ba45d2d841b3a08e01f845e60d723fec023eb4c9663</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2010</creationdate><topic>Animals</topic><topic>Anti-Anxiety Agents - chemical synthesis</topic><topic>Anti-Anxiety Agents - chemistry</topic><topic>Anti-Anxiety Agents - pharmacology</topic><topic>Antidepressive Agents - chemical synthesis</topic><topic>Antidepressive Agents - chemistry</topic><topic>Antidepressive Agents - pharmacology</topic><topic>Biological and medical sciences</topic><topic>Imidazolidines - chemical synthesis</topic><topic>Imidazolidines - chemistry</topic><topic>Imidazolidines - pharmacology</topic><topic>Magnetic Resonance Spectroscopy</topic><topic>Medical sciences</topic><topic>Mice</topic><topic>Models, Molecular</topic><topic>Motor Activity - drug effects</topic><topic>Neuropharmacology</topic><topic>Neurotransmitters. Neurotransmission. Receptors</topic><topic>Pharmacology. Drug treatments</topic><topic>Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer</topic><topic>Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer..., (alzheimer disease)</topic><topic>Psycholeptics: tranquillizer, neuroleptic</topic><topic>Psychology. Psychoanalysis. Psychiatry</topic><topic>Psychopharmacology</topic><topic>Rats</topic><topic>Serotonin 5-HT1 Receptor Agonists</topic><topic>Serotonin Receptor Agonists - chemical synthesis</topic><topic>Serotonin Receptor Agonists - chemistry</topic><topic>Serotonin Receptor Agonists - pharmacology</topic><topic>Serotoninergic system</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>CZOPEK, Anna</creatorcontrib><creatorcontrib>BYRTUS, Hanna</creatorcontrib><creatorcontrib>KOLACZKOWSKI, Marcin</creatorcontrib><creatorcontrib>PAWLOWSKI, Maciej</creatorcontrib><creatorcontrib>DYBALA, Małgorzata</creatorcontrib><creatorcontrib>NOWAK, Gabriel</creatorcontrib><creatorcontrib>TATARCZYNSKA, Ewa</creatorcontrib><creatorcontrib>WESOLOWSKA, Anna</creatorcontrib><creatorcontrib>CHOJNACKA-WOJCIK, Ewa</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>European journal of medicinal chemistry</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>CZOPEK, Anna</au><au>BYRTUS, Hanna</au><au>KOLACZKOWSKI, Marcin</au><au>PAWLOWSKI, Maciej</au><au>DYBALA, Małgorzata</au><au>NOWAK, Gabriel</au><au>TATARCZYNSKA, Ewa</au><au>WESOLOWSKA, Anna</au><au>CHOJNACKA-WOJCIK, Ewa</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Synthesis and pharmacological evaluation of new 5-(cyclo)alkyl-5-phenyl- and 5-spiroimidazolidine-2,4-dione derivatives. Novel 5-HT1A receptor agonist with potential antidepressant and anxiolytic activity</atitle><jtitle>European journal of medicinal chemistry</jtitle><addtitle>Eur J Med Chem</addtitle><date>2010-04-01</date><risdate>2010</risdate><volume>45</volume><issue>4</issue><spage>1295</spage><epage>1303</epage><pages>1295-1303</pages><issn>0223-5234</issn><eissn>1768-3254</eissn><coden>EJMCA5</coden><abstract>The synthesis of 5-(cyclo)alkyl-5-phenyl- and 5-spiroimidazolidine-2,4-dione derivatives with an arylpiperazinylpropyl moiety (12-23) and their in vitro and in vivo pharmacological properties and molecular characteristics were described. The investigated compounds exhibited high affinity for 5-HT(1A) (13-22) and 5-HT(2A) (18, 20, 21, 23) receptors and diversified pharmacological profile. Compounds 17, 20 and 22 showed antagonistic, partial agonistic and agonistic activity, respectively, toward 5-HT(1A) receptor and they were investigated as potential antidepressants and/or anxiolytics. The most interesting compound 22 (1-[3-(4-(2-methoxyphenyl)piperazin-1-yl)propyl]-3',4'-dihydro-2'H-spiro[imidazolidine-4,1'-naphthalene]-2,5-dione), a pre- and postsynaptic 5-HT(1A) receptor agonist produced an antidepressant-like effect, which was more pronounced than that of imipramine in the forced swim test in mice, without affecting locomotor activity. Moreover, compound 22 produced a weak anxiolytic-like effect in the four-plate test in mice. Molecular docking studies of compound 22 to the homology model of the 5-HT(1A) receptor showed that a 3',4'-dihydro-2'H-spiro[imidazolidine-4,1'-naphthalene]-2,5-dione moiety played an important role in stabilizing the ligand-receptor complex.</abstract><cop>Kidlington</cop><pub>Elsevier</pub><pmid>20060623</pmid><doi>10.1016/j.ejmech.2009.11.053</doi><tpages>9</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0223-5234 |
ispartof | European journal of medicinal chemistry, 2010-04, Vol.45 (4), p.1295-1303 |
issn | 0223-5234 1768-3254 |
language | eng |
recordid | cdi_proquest_miscellaneous_733707447 |
source | ScienceDirect Journals |
subjects | Animals Anti-Anxiety Agents - chemical synthesis Anti-Anxiety Agents - chemistry Anti-Anxiety Agents - pharmacology Antidepressive Agents - chemical synthesis Antidepressive Agents - chemistry Antidepressive Agents - pharmacology Biological and medical sciences Imidazolidines - chemical synthesis Imidazolidines - chemistry Imidazolidines - pharmacology Magnetic Resonance Spectroscopy Medical sciences Mice Models, Molecular Motor Activity - drug effects Neuropharmacology Neurotransmitters. Neurotransmission. Receptors Pharmacology. Drug treatments Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer..., (alzheimer disease) Psycholeptics: tranquillizer, neuroleptic Psychology. Psychoanalysis. Psychiatry Psychopharmacology Rats Serotonin 5-HT1 Receptor Agonists Serotonin Receptor Agonists - chemical synthesis Serotonin Receptor Agonists - chemistry Serotonin Receptor Agonists - pharmacology Serotoninergic system |
title | Synthesis and pharmacological evaluation of new 5-(cyclo)alkyl-5-phenyl- and 5-spiroimidazolidine-2,4-dione derivatives. Novel 5-HT1A receptor agonist with potential antidepressant and anxiolytic activity |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-26T18%3A07%3A27IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Synthesis%20and%20pharmacological%20evaluation%20of%20new%205-(cyclo)alkyl-5-phenyl-%20and%205-spiroimidazolidine-2,4-dione%20derivatives.%20Novel%205-HT1A%20receptor%20agonist%20with%20potential%20antidepressant%20and%20anxiolytic%20activity&rft.jtitle=European%20journal%20of%20medicinal%20chemistry&rft.au=CZOPEK,%20Anna&rft.date=2010-04-01&rft.volume=45&rft.issue=4&rft.spage=1295&rft.epage=1303&rft.pages=1295-1303&rft.issn=0223-5234&rft.eissn=1768-3254&rft.coden=EJMCA5&rft_id=info:doi/10.1016/j.ejmech.2009.11.053&rft_dat=%3Cproquest_cross%3E733707447%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c336t-b152ef9e7f871bef7b9164ba45d2d841b3a08e01f845e60d723fec023eb4c9663%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=733707447&rft_id=info:pmid/20060623&rfr_iscdi=true |